The operating results of the semiconductor cryogenics business had been included in the Brooks Semiconductor Solutions Group segment before the plan of disposition.
The acquisition of Tec-Sem has expanded the Company’s contamination control solutions business within the Brooks Semiconductor Solutions Group segment.
acquisition during fiscal year 2018.
During the three months ended June 30, 2019, and the period since acquisition, net income included $3.3 million and $8.2 million, respectively, related to amortization expense of acquired intangible assets.
serving scientific and business operations functions.
During the nine months ended June 30, 2019, the net income included $0.2 million related to the step-up in value of the acquired inventories and $2.2 million related to amortization expense of acquired intangible assets.
Net foreign currency transaction and remeasurement losses totaled $0.5 million and $0.6 million, respectively, during the three months ended June 30, 2019 and 2018 and $1.1 million and $3.1 million, respectively, during the nine months ended June 30, 2019 and 2018.
The acquisition of 4titude has expanded the Company’s existing offerings of consumables and instruments within the Brooks Life Sciences segment.
Amortization expense for intangible assets was $26.2 million and $17.7 million, respectively, during the nine months ended June 30, 2019 and 2018.
The Company collected $0.4 million from the escrow related to the delivery of the technology during the second quarter of fiscal year 2019.
During the three months ended March 31, 2019, the Company identified a misclassification related to the presentation of the product and service revenue and the cost of product and service revenue related to the GENEWIZ Group (“GENEWIZ”) in the Company's Consolidated Statements of Operations for the three months ended December 31, 2018.
The Company recorded an income tax expense of $7.3 million and $0.4 million, respectively, during the three and nine months ended June 30, 2019.The increase of $2.2 million during the third quarter of fiscal year 2019 as compared to the corresponding period of fiscal year 2018 reflects higher expense of $1.2 million within the Brooks Life Sciences segment and $1.0 million within the Brooks Semiconductor Solutions Group segment.
We reported gross margins of 41.0% for the three months ended June 30, 2019 compared to 38.8% for the corresponding period of the prior fiscal year.
We reported gross margins of 40.6% for the nine months ended June 30, 2019 compared to 38.9% for the corresponding period of the prior fiscal year.
The $1.9 million decrease during the nine months ended June 30, 2019 as compared to the corresponding period of fiscal 2018 was primarily attributable to lower foreign currency exchange losses.
Research and development expenses were $14.2 million and $41.5 million, respectively, during the three and nine months ended June 30, 2019 as compared to $12.0 million and $34.8 million, respectively, during the corresponding periods of the prior fiscal year.
The syndication to a new group of lenders during the second quarter of fiscal 2019 met the criteria of a debt extinguishment and therefore the amortization of the deferred financing costs associated with the origination of the incremental term loan was accelerated and recorded as a loss on extinguishment of debt in our statement of operations.